Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association Boston Scientific Corporation (NYSE: BSX) today announced that results from studies involving the Company's Women's Health products will be presented ...

NATICK, Mass. , Aug. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that results from studies involving the Company's Women's Health products will be presented at the Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA). The presentations will feature Boston Scientific's pelvic floor reconstruction systems and mid-urethral sling systems. The meeting will be held August 23-27 in Toronto .

Schedule of Key Presentations (All times are local; all events take place in the Metro Toronto Convention Centre.)

Wednesday, August 25

Poster Presentation: Ultrasonographic Scan Evaluation of Synthetic Mesh. Vincent Letouzey, M.D., will present a poster titled "Ultrasonographic Scan Evaluation of Synthetic Mesh Used for Vaginal Cystocele Repair Comparing Four Arms Transobturator Techniques to Anterior Bilateral Sacrospinous Ligament and Arcus Tendinous Suspension," during Poster Session 6 (Urodynamics and Imaging) at 5:10 p.m. in Room 701. The study evaluates post-procedure mesh contraction and placement of the Ugytex ™ Transobturator Mesh and Pinnacle ® Mesh using ultrasonography.

Friday, August 27

Poster Presentation: Evaluation of Lightweight Meshes. Barry O'Reilly, M.D., will present a poster titled "Evaluation of Local Tolerance of Lightweight Meshes in an Animal Model," during Poster Session 29 (Prolapse Surgery) at 3:45 pm in Room 717. The study assesses the local tolerance of the Polyform ® Mesh and VitaMesh ® Implant Pelvic Floor Reconstruction (PFR) meshes to other commercially available polypropylene meshes in modulating wound healing response.

Accepted Abstracts (Available at the ICS/IUGA booth and websites.)

This abstract describes results of a study to evaluate the force required to remove a mesh leg from the sacrospinous ligaments if a surgeon feels the initial placement was not adequate and that readjustment is needed. The pull-out forces of the Pinnacle® PFR Kit and the Elevate® PFR Kit were measured and evaluated.

Ugytex is a trademark of Sofradim Production. VitaMesh is a registered trademark of Proxy Biomedical.

The International Continence Society is a society for medical professionals concerned with furthering education, scientific research and clinical practice, and with removing the stigma of incontinence. For more information, please visit: www.icsoffice.org .

The International Urogynecological Association is a non-profit international organization dedicated to the advancement of urogynecological knowledge around the world through education and the promotion of basic and clinical research on disorders of the female pelvic floor. For more information, please visit: www.iuga.org .

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things our product performance, regulatory approval of our products, clinical studies, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

SOURCE Boston Scientific Corporation